Skip to main content
. 2020 Jul;8(14):881. doi: 10.21037/atm-20-5080

Figure 4.

Figure 4

Chest computed tomography (CT) changes in two critically ill COVID-19 patients before and after Tocilizumab. Only two patients underwent CT examination before and after medication. For Patient 3, the first chest CT scan showed significant ground-glass opacity on both lungs one day after the use of Tocilizumab. On days 7 and 13 of Tocilizumab use, the lung lesions on the chest CT imaging were significantly reduced, accompanied by improved clinical conditions. For Patient 6, the first chest CT scan showed significant ground-glass opacity on both lungs one day after the use of Tocilizumab. At days 6 and 12, the lung lesions on the chest CT scan were significantly reduced, accompanied by improved clinical conditions. Black arrow marked the location of inflammatory lesions.